Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma

Brian A. Van Tine, MD, PhD
Published: Wednesday, Jun 03, 2015



Brian A. Van Tine, MD, PhD, Assistant Professor  Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses  trabectedin (Yondelis) for the treatment of soft tissue sarcomas.
 
Trabectedin has been available for over a decade outside of the United States for the treatment of leiomyosarcoma and liposarcoma. It is available at compassionate use centers throughout the United States, but is not currently FDA approved.
 
It is an exciting drug that has excellent progression-free survival and response rates in leiomyosarcoma and liposarcoma patients, says Van Tine.

Considering its positive results in multiple clinical trials, Van Tine hopes that the FDA will approve the drug for leiomyosarcoma and liposarcoma in the near future.

<<< View more from the 2015 ASCO Annual Meeting



Brian A. Van Tine, MD, PhD, Assistant Professor  Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses  trabectedin (Yondelis) for the treatment of soft tissue sarcomas.
 
Trabectedin has been available for over a decade outside of the United States for the treatment of leiomyosarcoma and liposarcoma. It is available at compassionate use centers throughout the United States, but is not currently FDA approved.
 
It is an exciting drug that has excellent progression-free survival and response rates in leiomyosarcoma and liposarcoma patients, says Van Tine.

Considering its positive results in multiple clinical trials, Van Tine hopes that the FDA will approve the drug for leiomyosarcoma and liposarcoma in the near future.

<<< View more from the 2015 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x